Glutathione — Research Overview
Chemical Name: Gamma-L-glutamyl-L-cysteinyl-glycine Also Known As: GSH, reduced glutathione, L-glutathione, GSH, the master antioxidant Structure: Tripeptide composed of three amino acids — glutamic acid, cysteine, and glycine — linked by peptide bonds. The cysteine residue contains the reactive thiol (-SH) group responsible for glutathione’s antioxidant and detoxification functions. Molecular Formula: C10H17N3O6S Molecular Weight: 307.32 daltons Redox States: Glutathione exists in two interconvertible forms: reduced glutathione (GSH) — the active antioxidant form — and oxidized glutathione disulfide (GSSG), formed when two GSH molecules donate electrons to neutralize reactive oxygen species. Intracellular GSH is recycled back from GSSG by glutathione reductase using NADPH as a cofactor. Endogenous Production: Synthesized in virtually all human cells through a two-step enzymatic process. Step 1: Glutamic acid and cysteine are ligated by gamma-glutamylcysteine ligase (GCL) to form gamma-glutamylcysteine. Step 2: Glycine is added by glutathione synthase. Both steps require ATP. The liver is the primary site of GSH synthesis and export, supplying peripheral tissues through the circulation. Category: Endogenous tripeptide antioxidant / master antioxidant / cellular redox regulator / detoxification cofactor
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of any applicable approved pharmaceutical indications. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Glutathione?
Glutathione is the most abundant endogenous antioxidant synthesized in human cells, present at millimolar concentrations in the cytoplasm of virtually every cell in the body. It is often referred to as the master antioxidant because of the central organizing role it plays in the cellular antioxidant defense network — not only scavenging reactive oxygen species directly through its own thiol group, but also regenerating other antioxidants including vitamins C and E back to their active reduced forms, enabling them to continue neutralizing oxidative stress.
The importance of glutathione extends far beyond simple free radical scavenging. It functions as the essential cofactor for a family of glutathione S-transferase enzymes that conjugate glutathione to electrophilic xenobiotics, carcinogens, and toxins, rendering them water-soluble and facilitating their excretion — making glutathione central to the liver’s detoxification capacity. Glutathione peroxidases (GPx) use GSH to reduce hydrogen peroxide and lipid peroxides, protecting cell membranes from oxidative damage. Glutathione also participates in redox signaling through the reversible S-glutathionylation of protein cysteine residues, modulating the activity of hundreds of enzymes and transcription factors in a redox-dependent manner. It supports DNA and RNA synthesis, regulates cell proliferation and apoptosis, and is essential for maintaining mitochondrial function and integrity.
Glutathione levels decline with age, chronic disease, oxidative stress, certain medications, poor nutrition, and environmental toxin exposure. This decline has been associated in published research with accelerated aging biology, impaired immune function, increased cancer risk, hepatic disease progression, and neurodegeneration — particularly in conditions such as Parkinson’s disease where GSH depletion in the substantia nigra is one of the earliest and most reproducible biomarkers of pathology.
Mechanism of Action
Direct free radical scavenging: The thiol group of the cysteine residue in GSH donates hydrogen atoms to neutralize reactive oxygen species including superoxide radicals, hydroxyl radicals, and peroxynitrites, converting them to less reactive or non-reactive molecules. In this process GSH is oxidized to GSSG. The GSH:GSSG ratio is a commonly used biomarker of cellular oxidative stress — a low ratio indicates high oxidative burden.
Glutathione peroxidase-mediated reduction: GPx enzymes use two molecules of GSH to reduce hydrogen peroxide (H2O2) to water, and lipid hydroperoxides to their corresponding alcohols. This is the primary enzymatic mechanism by which cells protect membrane lipids from peroxidation and remove the hydrogen peroxide produced as a byproduct of aerobic metabolism.
Glutathione S-transferase mediated detoxification: GST enzymes catalyze the nucleophilic addition of the GSH thiol to electrophilic centers on xenobiotics, drugs, environmental pollutants, and carcinogens, forming water-soluble glutathione conjugates that are exported from cells and excreted via bile or urine. This is one of the liver’s primary phase 2 detoxification mechanisms.
Antioxidant recycling: GSH regenerates ascorbate (vitamin C) from its oxidized form (dehydroascorbate) through the action of dehydroascorbate reductase, and regenerates alpha-tocopherol (vitamin E) from the tocopheroxyl radical, enabling both antioxidants to continue their protective functions after donating electrons to neutralize free radicals.
S-glutathionylation and redox signaling: GSH participates in the post-translational modification of protein cysteine residues through reversible S-glutathionylation — the addition of a glutathione moiety. This modification protects reactive cysteines from irreversible oxidation during oxidative stress and serves as a redox-sensitive regulatory switch that modulates the activity of numerous proteins including enzymes, structural proteins, and transcription factors.
Mitochondrial protection: A distinct pool of glutathione within the mitochondrial matrix (mGSH) protects the inner mitochondrial membrane from lipid peroxidation, prevents oxidative damage to mitochondrial DNA, and supports the respiratory chain electron transport complexes against oxidative inactivation. Depletion of mGSH is closely associated with mitochondrial dysfunction and the cellular energy deficits seen in numerous disease states.
Published Research
Study 1 — Randomized Controlled Trial: Oral Glutathione Supplementation and Body Store Increases
Authors: Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE Year: 2015 Journal: European Journal of Nutrition PMID: 24791752 Full text: https://pubmed.ncbi.nlm.nih.gov/24791752/
This 6-month randomized double-blind placebo-controlled trial in 54 non-smoking healthy adults examined whether oral glutathione supplementation could meaningfully increase body compartment GSH stores — directly addressing the pharmacokinetic question of whether oral GSH is bioavailable in humans despite concerns about gastrointestinal degradation.
GSH levels in blood increased significantly after 1, 3, and 6 months versus baseline at both the 250 mg and 1,000 mg daily dose groups, with increases being dose and time dependent.
At 6 months, mean GSH levels increased 30 to 35% in erythrocytes, plasma, and lymphocytes, and 260% in buccal mucosal cells in the high-dose group (P less than 0.05) — demonstrating that oral supplementation produced measurable and meaningful increases across multiple body compartments.
A reduction in oxidative stress was indicated in both dose groups by decreases in the oxidized to reduced glutathione ratio in whole blood at 6 months, providing a functional biomarker of antioxidant improvement.
Natural killer cell cytotoxicity increased more than twofold in the high-dose group versus placebo at 3 months (P less than 0.05), demonstrating an immune function effect alongside the antioxidant effects.
GSH levels returned toward baseline after a 1-month washout period, confirming that ongoing supplementation is required to maintain elevated body stores.
The authors concluded that for the first time these findings demonstrated that daily oral GSH supplementation was effective at increasing body compartment stores of GSH in healthy adults — establishing oral bioavailability in humans.
Study 2 — Early Pilot Study: Intravenous Glutathione in Parkinson’s Disease
Authors: Sechi G, Deledda MG, Bua G et al. Year: 1996 Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry PMID: 8938817 Full text: https://pubmed.ncbi.nlm.nih.gov/8938817/
This open-label pilot study in 9 patients with early, untreated Parkinson’s disease examined the effect of intravenous glutathione administration on clinical disability, building on established evidence that GSH is profoundly deficient in the substantia nigra of PD patients.
GSH was administered intravenously at 600 mg twice daily for 30 days. Patients were then followed at 1-month intervals for 2 to 4 months before initiation of carbidopa-levodopa therapy.
All patients improved significantly after GSH therapy, with a 42% decline in disability on clinical rating scales — a striking magnitude of improvement in an open-label pilot context.
The improvement persisted for 2 to 4 months after the cessation of GSH therapy, suggesting a duration of effect beyond the period of active administration.
The authors noted that GSH deficiency in the substantia nigra parallels disease severity in PD, suggesting that the magnitude of nigral GSH depletion may indicate an opportunity for therapeutic support of nigral cells.
This study, while open-label and small, provided the rationale for subsequent randomized controlled investigation of glutathione in Parkinson’s disease and remains the foundational published human evidence for IV glutathione in this condition.
Study 3 — Randomized Phase I/IIa Trial: Intranasal Glutathione in Parkinson’s Disease
Authors: Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ Year: 2015 Journal: Movement Disorders PMID: 26230671 Full text: https://pubmed.ncbi.nlm.nih.gov/26230671/
This randomized double-blind Phase I/IIa trial was the first placebo-controlled investigation of glutathione by intranasal delivery in Parkinson’s disease — examining whether intranasal GSH could reach the CNS and produce measurable clinical effects while avoiding the limitations of systemic IV administration.
The trial examined the safety, tolerability, and preliminary efficacy of intranasal glutathione in PD patients over a 3-month intervention period with 1-month washout.
The study was designed primarily as a safety and Phase I dose-finding trial. Multiple clinical outcome measures were tracked including Unified Parkinson’s Disease Rating Scale (UPDRS), Montreal Cognitive Assessment (MoCA), and olfactory function.
The trial established safety and tolerability of intranasal GSH delivery, supporting the rationale for larger efficacy trials using this delivery route.
The authors concluded that depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease-modifying strategy, calling for larger adequately powered Phase II trials to assess clinical efficacy.
Study 4 — Meta-Analysis: Glutathione as Treatment for Parkinson’s Disease
Authors: Wang S et al. (Clinical Medical College of Yangzhou University) Year: 2021 Journal: Experimental and Therapeutic Medicine PMID: 33376507 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7751460/
This systematic meta-analysis synthesized evidence from 7 randomized controlled trials involving 450 participants to assess the efficacy and safety of glutathione treatment in Parkinson’s disease — providing the most comprehensive quantitative assessment of this evidence base to date.
A statistically significant difference was found between the GSH and control groups in UPDRS III (motor subscale) scores: standard mean difference -0.48 (95% CI -0.88 to -0.08, P equal to 0.02) — indicating a modest but statistically significant improvement in motor symptoms with glutathione treatment.
Glutathione peroxidase levels were also significantly higher in the GSH group: SMD 1.88 (95% CI 0.52 to 3.24, P equal to 0.007), confirming engagement of the glutathione peroxidase antioxidant system.
No statistically significant differences were found in UPDRS I (mentation and behavior) or UPDRS II (activities of daily living) between groups, indicating that the motor benefit was not accompanied by measurable cognitive or functional improvements at the doses and durations studied.
Subgroup analyses revealed that the dosage used (300 versus 600 mg) was an influencing factor for UPDRS III outcomes, with higher dosing associated with greater motor benefit.
Side effects were not significantly different between GSH and control groups, confirming a favorable safety profile.
The authors concluded that GSH may mildly improve motor scores in PD but not at the expense of increased adverse events, while acknowledging that included studies were small and the clinical evidence base remains insufficient for definitive therapeutic recommendations.
Study 5 — Randomized Controlled Trial: Oral Glutathione and Systemic Oxidative Stress Biomarkers
Authors: Allen J, Bradley RD Year: 2011 Journal: Alternative Medicine Review PMID: 21875351 Full text: https://pubmed.ncbi.nlm.nih.gov/21875351/
This randomized double-blind placebo-controlled trial in 40 healthy adults examined the effect of oral glutathione supplementation (500 mg twice daily) on validated biomarkers of systemic oxidative stress over 4 weeks, directly testing whether oral GSH produces measurable systemic antioxidant effects.
No significant changes were observed in urinary F2-isoprostanes (a validated lipid peroxidation biomarker) or urinary 8-hydroxy-2′-deoxyguanosine (a validated DNA oxidation biomarker) between treatment and placebo groups at 4 weeks.
Total reduced, oxidized, and ratio measures of erythrocyte GSH status were also unchanged at 4 weeks.
The authors concluded that no significant changes were observed in biomarkers of systemic oxidative stress in this short-term oral glutathione supplementation trial in healthy adults.
This study is important for providing balanced context alongside the Richie et al. 2015 trial: short-term oral supplementation in already-healthy individuals may not produce detectable changes in oxidative stress biomarkers even when body compartment GSH levels are modestly elevated — a finding consistent with the homeostatic regulation of redox balance in healthy subjects and the importance of longer supplementation duration and baseline oxidative stress burden in study design.
Study 6 — Intravenous Glutathione for Renal Protection: Contrast Nephropathy Prevention
Authors: Ferrario F, Castoldi G, Marzano L et al. Year: 2011 Journal: Saudi Journal of Kidney Diseases and Transplantation PMID: 21127883 Full text: https://pubmed.ncbi.nlm.nih.gov/21127883/
This clinical study examined whether intravenous glutathione could prevent contrast medium-induced oxidative stress and renal damage in patients undergoing coronary angiography, comparing GSH to oral N-acetylcysteine (NAC) — the established prophylactic agent for contrast-induced nephropathy.
In the control group without prophylaxis, serum GSH levels fell by 9.4% at 2 hours after coronary angiography (P less than 0.01), confirming that contrast medium exposure acutely depletes systemic glutathione through oxidative stress.
The decrease in serum GSH was prevented in the intravenous GSH group (-1.8%, not significant) but not in the oral NAC group (-10.0%, P less than 0.05) — directly demonstrating superior acute renal antioxidant protection with intravenous GSH compared to the oral NAC standard.
The authors concluded that the renal damage from contrast medium-induced oxidative stress occurs soon after angiography and that intravenous GSH is more effective in preventing the oxidative stress than oral NAC, suggesting that GSH may be a potentially more effective therapeutic strategy against contrast-induced nephropathy in high-risk patients.
The Glutathione Research Landscape: Key Themes and Context
The research base for glutathione spans five decades and encompasses oxidative biology, clinical therapeutic applications, bioavailability pharmacology, and disease-specific investigation. Several important themes emerge from the cumulative evidence.
Depletion is a consistent disease biomarker: GSH depletion has been documented across a broad range of conditions including Parkinson’s disease (substantia nigra), Alzheimer’s disease, HIV infection, type 2 diabetes, liver cirrhosis, chronic kidney disease, and cancer — establishing low GSH as both a marker of oxidative burden and a potential therapeutic target across multiple pathologies.
Route of administration critically determines pharmacology: The research consistently demonstrates that the route of glutathione administration determines its bioavailability and pharmacological profile significantly. Oral GSH faces gastrointestinal enzymatic degradation that limits but does not entirely prevent systemic bioavailability — demonstrated by the Richie 2015 trial showing increases over 6 months. Intravenous GSH achieves rapid complete systemic bioavailability but produces non-physiological plasma concentrations that exceed cellular uptake capacity. Intranasal administration offers a potential route for CNS delivery. The clinical evidence shows that route selection must be matched to the specific research application.
The bioavailability debate: A substantial published literature debates whether exogenous glutathione — particularly oral glutathione — raises intracellular glutathione levels meaningfully enough to produce therapeutic effects. The Richie 2015 RCT demonstrated 30 to 35% increases in erythrocyte and plasma GSH at 6 months with oral supplementation. The Allen 2011 RCT found no effect on oxidative stress biomarkers at 4 weeks. These findings are not necessarily contradictory — duration of supplementation, baseline oxidative burden, dosing, and outcome measure selection all influence results.
N-acetylcysteine (NAC) as precursor: Because cysteine is the rate-limiting amino acid for GSH synthesis and is rapidly oxidized as free cysteine, NAC — a stable cysteine prodrug — has been extensively studied as an indirect approach to raising intracellular GSH by providing cysteine substrate. While NAC has demonstrated clinical efficacy in multiple contexts (acetaminophen toxicity, pulmonary applications, psychiatric conditions), evidence that NAC meaningfully raises cellular GSH in non-deficient subjects is inconsistent in the published literature.
Reductive stress as a theoretical concern: Some published commentary has raised the question of whether supraphysiological GSH concentrations from intravenous infusion could cause reductive stress — a condition of excessive reducing equivalents that can disrupt mitochondrial electron transport and impair immune function. This remains a theoretical concern supported by modeling rather than by robust human clinical evidence, but warrants consideration in research protocol design for high-dose IV glutathione studies.
Additional Research Areas
Liver disease: Glutathione is essential for hepatic detoxification and phase 2 metabolism. GSH depletion is associated with progression of non-alcoholic fatty liver disease, alcoholic liver disease, and drug-induced hepatotoxicity. GSH supplementation has been studied in liver disease contexts internationally, particularly in Asian clinical literature.
Cancer adjunct research: Glutathione has been investigated as a cytoprotective adjunct to platinum-based chemotherapy (cisplatin, oxaliplatin), where it may reduce peripheral neuropathy and nephrotoxicity associated with platinum compounds without reducing antitumor efficacy. This application has been studied in clinical trials primarily in oncology research settings.
Cardiovascular protection: GSH is relevant to cardiovascular research through its role in reducing oxidized LDL, protecting vascular endothelium from oxidative damage, and modulating platelet aggregation through thiol-dependent mechanisms.
Skin biology: Glutathione’s ability to shift melanin synthesis from eumelanin (brown-black) toward phaeomelanin (yellow-red) through inhibition of tyrosinase has generated research interest in hyperpigmentation and skin pigmentation modulation.
Current Research Status
Glutathione is not FDA-approved as a drug for any specific indication but is widely used as a pharmaceutical agent in countries outside the United States — particularly in Japan and Italy where IV glutathione is an approved adjunct therapy for liver disease and chemotherapy neuroprotection. In the United States, it is available as a dietary supplement and may be compounded for intravenous use by licensed compounding pharmacies for specific patient needs outside of FDA-approved indications.
Active research areas include Parkinson’s disease neuroprotection (Phase II trials ongoing), NAFLD treatment, chemotherapy cytoprotection optimization, intranasal delivery for CNS conditions, and investigation of formulation approaches (liposomal, sublingual, nebulized) that improve bioavailability compared to standard oral dosing.
Reconstitution Note
Glutathione for injection is supplied as a lyophilized powder. Bacteriostatic water or sterile water for injection is the standard reconstitution solvent. Glutathione dissolves readily in water at the concentrations used in research applications. It is light-sensitive — protect reconstituted solutions from light immediately. Reduced glutathione (GSH) is susceptible to oxidation in solution; use promptly after reconstitution and do not store reconstituted solutions for extended periods. Always confirm the recommended solvent and handling protocol against the specific lot datasheet before use.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages. Glutathione in solution is particularly sensitive to oxidation and light exposure — use promptly after reconstitution. Avoid repeated freeze-thaw cycles of reconstituted solutions. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible discoloration or signs of oxidation.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard compound handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Glutathione product page: https://roguecompounds.com/product/glutathione/